Textazo

Method of action: Bactericidal

Treatment option: Abscess, Influenza, Infection, Complicated Skin And Skin Structure Infection, Peritonitis, Pneumonia, Prevent Infections, Hospital Acquired Pneumonia, Pelvic Infections, Cellulite

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Textazo

Quick Facts

Property	Description
Active ingredient	Piperacillin and Tazobactam
Form	Sterile Powder for Solution for Infusion
Pharmacological class	Penicillins / Beta-lactamase Inhibitors
Common purpose	Combatting severe bacterial infections
Origin	Semisynthetic

What Type of Medicine is Textazo?

Textazo refers to the fixed-dose combination product containing the active compounds Piperacillin and Tazobactam. It is formally classified as an Antiinfective Agent belonging to the pharmacological group of Penicillins / Beta-lactamase Inhibitors and is recognized as an extended-spectrum semisynthetic beta-lactam antibiotic formulation. This dual-component medicine is designed for use in critical care, being a preferred choice for serious infections in hospital settings.

Composition and Formulation

The core structure of Textazo involves two distinct active pharmaceutical ingredients: Piperacillin Sodium Salt, which functions as the primary extended-spectrum beta-lactam antibiotic, and Tazobactam Sodium Salt, which serves as the protective beta-lactamase inhibitor. This product is typically supplied as a sterile cryodesiccated powder for solution for infusion, requiring a liquid solvent for reconstitution before administration. The drug is strictly intended for parenteral (intravenous) delivery, which is essential to ensure the entire dose is rapidly available in the bloodstream for systemic bacterial challenges.

Why are Piperacillin and Tazobactam Used Together?

The rationale for combining the Piperacillin antibiotic with the Tazobactam inhibitor is to achieve a powerful synergistic action that effectively defeats bacterial defenses. Piperacillin performs the main attack by inhibiting cell wall synthesis and providing bactericidal activity. Crucially, Tazobactam functions as an irreversible inhibitor of the beta-lactamase enzymes that bacteria use to destroy the drug. This protective strategy is critical, as it significantly broadens the drug's antibacterial spectrum and ensures the treatment is highly effective against a wider, often resistant, range of organisms.

What side effects are possible with Textazo?

Possible Side Effects and Safety Information

This section outlines the adverse reactions and safety considerations for Textazo (Piperacillin/Tazobactam) as documented in official government regulatory sources, such as the U.S. FDA Prescribing Information and the European Medicines Agency (EMA) Summary of Product Characteristics (SmPC).

Frequency-Classified Adverse Reactions

Adverse effects are categorized by their documented frequency of occurrence:

Very Common (Affecting 1 in 10 or more people): Diarrhea.
Common (Affecting up to 1 in 10 people): Gastrointestinal issues (such as nausea, vomiting, and constipation), blood cell changes (including anemia, thrombocytopenia, and eosinophilia), skin reactions (rash, pruritus), and headaches.
Uncommon: More significant adverse effects, including kidney problems (renal failure), low blood pressure (hypotension), and seizures (convulsions).
Rare/Not Known: Serious skin conditions (e.g., Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis), severe allergic reactions (anaphylaxis), and serious hematological disorders (agranulocytosis, pancytopenia).

Serious Safety Considerations

The most serious documented risks include potentially life-threatening severe allergic reactions and rare but serious skin and blood disorders. Clostridioides difficile-associated diarrhea (CDAD) is also a documented risk, ranging from mild diarrhea to fatal colitis. Furthermore, the official label notes a potential for nephrotoxicity (acute kidney injury), particularly in critically ill patients or those receiving concurrent vancomycin.

Specific Safety Requirements

Hypersensitivity Restriction: Textazo is strictly contraindicated in individuals with a history of severe allergic reactions to penicillins or any other beta-lactam antibiotics.
Renal Impairment: For patients with reduced kidney function, dosage adjustment is required to prevent high drug concentrations, which may lead to central nervous system toxicity, including seizures.
Duration Monitoring: Patients receiving the medicine for longer than 21 days are advised to have their blood counts monitored regularly due to the increased risk of certain blood cell changes (e.g., neutropenia).

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Textazo requires immediate medical attention. Taking more than the prescribed amount of Textazo can lead to severe adverse health effects.

Recognizing Potential Overdose

Documented clinical manifestations of Textazo overdose primarily affect the gastrointestinal and nervous systems. Symptoms that have been reported include:

Nausea, vomiting, and diarrhea
Neuromuscular excitability (increased sensitivity of muscles and nerves)
Convulsions (seizures)

Emergency Actions and Seeking Help

Urgent medical care is required in all cases of suspected overdose. The official procedure is to contact a healthcare professional, a hospital emergency department, or a regional Poison Control Centre immediately. This immediate action is necessary regardless of whether the individual is currently showing any symptoms. Do not wait for symptoms to develop or worsen before seeking emergency assistance. The rapid onset of serious complications, such as convulsions, necessitates prompt intervention from trained medical personnel.

Therapeutic Uses of Textazo

Quick Facts

Treats bacterial infections in various systems and organs.
Administered to manage complicated intra-abdominal infections and severe pneumonia.
Used for the treatment of complicated skin and soft tissue infections.
Indicated for specific gynecological and complicated urinary tract infections.
Employed as empirical therapy for fever associated with neutropenia.

Textazo is utilized for the treatment of moderate to severe bacterial infections caused by susceptible organisms. The primary therapeutic uses encompass infections in several critical body systems. The medication is indicated for the treatment of complicated intra-abdominal infections in adults and pediatric patients, which may involve conditions such as peritonitis or appendicitis with complications. It is also used to manage severe lower respiratory tract infections, including community-acquired pneumonia and hospital-acquired pneumonia.

Furthermore, the medication is administered for the treatment of complicated skin and soft tissue infections, including conditions like cellulitis, and for specific gynecological infections, such as pelvic inflammatory disease. Textazo is also indicated for complicated urinary tract infections in adults. A notable use is as empirical therapy for fever in patients who are neutropenic, where a bacterial infection is suspected. The benefit of this medication is its ability to broaden the antibacterial spectrum to address a range of bacterial pathogens that may otherwise be resistant.

Eligibility and Restrictions for Use

Who Can and Cannot Use Textazo?

The population eligibility for using Textazo (Piperacillin and Tazobactam) is strictly defined by regulatory documents, which establish groups for whom use is prohibited and those who require conditional use or careful monitoring.

Absolute Contraindications

Use is strictly contraindicated for individuals with a known history of severe allergic reactions (hypersensitivity) to Piperacillin, Tazobactam, any penicillin-class antibacterial, or related drugs like cephalosporins.

Age and Physiological Restrictions

Population Group	Eligibility Status (Regulatory Wording)
Adults	Established use for labeled indications.
Pediatric Patients	Approved for those mathbf2 months of age and older. Safety is not adequately characterized for infants younger than 2 months.
Renal Impairment	Use is permitted but restricted; dose and frequency must be adjusted based on the degree of impairment, including for dialysis patients.
Hepatic Impairment	No dosage adjustment is warranted due to hepatic cirrhosis alone.
Pregnancy/Lactation	Use is conditional; permitted only when clearly indicated and the expected therapeutic benefit outweighs the potential risks.

Eligibility is also restricted for patients with conditions like Hypokalemia or a history of seizures, who require close physiological monitoring as documented in official labeling.

What should I know about interactions with other medicines?

The documented interaction profile for Textazo (Piperacillin and Tazobactam) focuses on clinically significant interactions that alter drug exposure, reinforce therapeutic effects, or require specific administration constraints.

The co-administration of Probenecid, a uricosuric agent, is known to result in an increase and prolongation of plasma concentrations of both Piperacillin and Tazobactam. This is classified as a pharmacokinetic interaction due to the competitive inhibition of renal tubular secretion.

Timing-Based Interaction Rules

A critical requirement for administration involves Aminoglycosides (such as Gentamicin or Tobramycin). Because Textazo can lead to the in vitro inactivation of Aminoglycosides, the two must be administered separately and not combined in the same infusion fluid.

Mechanism of Action

The mechanism of Textazo involves a coordinated, two-pronged attack on the bacterial cell. The component Tazobactam acts first as an irreversible suicide inhibitor of bacterial Serine β-lactamase enzymes. This mechanism neutralizes the enzymatic defense that organisms use to chemically destroy the antibiotic. By permanently inactivating the β-lactamase, Tazobactam ensures the primary antibiotic remains intact to reach its target. This protective action restores functional activity against organisms that utilize β-lactamase as a defense. The Piperacillin component then proceeds to bind covalently to bacterial Penicillin-Binding Proteins (PBPs), a class of enzymes crucial for the final steps of building the cell's rigid peptidoglycan wall. Inhibiting PBP activity prevents the necessary cross-linking of the peptidoglycan structure, immediately compromising the cell's integrity. This structural failure causes the bacterium to rupture due to osmotic pressure, leading to microbial cell lysis and cell death, consistent with a bactericidal mechanism.

Dosage and Administration Information

How to Use Textazo: Administration Guidelines

Textazo is exclusively administered by Intravenous (IV) Infusion. The medicine is supplied as a sterile powder that must be reconstituted and diluted with an appropriate solution prior to delivery, as it cannot be taken by mouth.

Standardized Administration Parameters

Parameter	Instruction
Route	Intravenous (IV) Infusion only.
Infusion Time	Administered over a controlled period of 30 minutes.
Standard Adult Dose	3.375 g total drug (Piperacillin 3 g / Tazobactam 0.375 g).
Severe Infection Dose	4.5 g total drug (Piperacillin 4 g / Tazobactam 0.5 g).
Frequency	Typically administered in divided doses every 6 hours (q6h).

Population-Specific & Procedural Rules

Condition	Use Protocol
Renal Impairment	Mandatory dose or interval reduction for patients with a Creatinine Clearance le 40 mL/min. A supplemental dose is required after each hemodialysis session to account for drug removal.
Preparation Constraint	The product must be prepared and infused separately from certain other IV medications, such as aminoglycosides, due to the risk of inactivation.
Duration	Treatment courses typically range from 7 to 10 days, but may extend up to 14 days for severe infections like hospital-acquired pneumonia, with the final course length guided by clinical response.

These parameters establish a precise, standardized parenteral protocol. This structured regimen defines the exact dose amounts, the fixed infusion time, and necessary adjustments for compromised renal function, ensuring the medicine is administered according to the established constraints. The maximum daily dose is also governed by these standardized schedules.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Textazo (Piperacillin/Tazobactam)

This overview describes the types of scientific studies that have been conducted to evaluate Textazo for its approved uses. This summary focuses on what researchers examined, what was observed in the study populations, and what aspects of the study are still being explored, consistent with official regulatory evidence.

Evidence for Use in Complicated Intra-abdominal Infections (cIAI)

The research base for complicated intra-abdominal infections (such as peritonitis or complicated appendicitis) focuses on Textazo, supported by several large Randomized Controlled Trials (RCTs). These studies were studied for and designed to compare the measured outcomes of Textazo against other established broad-spectrum antibiotics.

In these research settings, studies explored outcomes related to Clinical Treatment Success, a measure describing how symptoms evolved in the observed populations. Researchers also monitored the eradication of bacteria from the infected sites and documented mortality rates. Findings from these comparisons indicate patterns of changes measured in the studies.

Evidence for Use in Severe Lower Respiratory Tract Infections

Textazo was studied for severe lung infections, including hospital-acquired pneumonia, through large Randomized Controlled Trials and specific supportive studies focused on delivery methods. These studies included critically ill adults and adolescents who were hospitalized and often required intensive care.

Research examined outcomes related to Clinical Treatment Success and Microbiological Eradication, which measured microbiological eradication rates. Trials also tracked and reported All-cause Mortality as an outcome. Findings describe patterns observed in some studies in these high-acuity settings where studies were conducted during periods of increased symptom activity.

Research Focus on Special Populations and Evidence Gaps

Research has explored the measured drug concentration patterns in pediatric patients and the elderly. For patients with impaired kidney function, research has explored patterns of drug processing, given that the drug relies significantly on the kidneys for clearance. Subgroup findings are uncertain in patients with multiple severe comorbidities.

Long-term effects are not fully established, as follow-up durations were limited to the short-to-intermediate term. There is limited information for long-term outcomes regarding the durability of the observed outcomes or the likelihood of infection recurrence. Research is ongoing to better understand how outcomes relate to changing bacterial resistance patterns.

Key Studies & References

Piperacillin/tazobactam in the treatment of intra-abdominal infection: a meta-analysis of randomized controlled trials

Frequently Asked Questions (FAQ)

Common questions about Textazo (FAQ)

Q: How should I store Textazo?

A: Textazo should typically be stored at room temperature, away from moisture and heat. It is important to keep the medication in its original container. Always refer to the specific storage instructions provided on the product labeling.

Q: What should I do if I miss a dose of Textazo?

A: If a dose is missed, individuals are generally advised to take it as soon as they remember, unless it is almost time for the next scheduled dose. If it is close to the next dose, the missed dose should be skipped. It is important to avoid taking two doses at once to compensate for a missed one. Specific guidance should come from a healthcare provider.

Q: Does Textazo interact with common pain relievers?

A: Potential drug interactions can exist between Textazo and various medications, including some common pain relievers. It is important to inform a healthcare provider of all current medications, including over-the-counter drugs, to assess the risk of interaction.

How should Textazo be stored and disposed of?

Official Storage and Disposal Requirements

Textazo (Piperacillin and Tazobactam for Injection) is a sterile powder with specific, regulated storage and disposal rules defined by government health authorities.

Storage Conditions

Condition	Regulatory Requirement
Unopened Powder	Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). Protect the contents from light by keeping the vial in its outer carton.
Reconstituted Solution	The solution must be used within 24 hours if stored at room temperature or within 48 hours if refrigerated at 2 C to 8 C. The solution must be visually inspected for particulates before use.

Disposal Rules

Textazo is a single-use product, and any unused portion or waste material must be discarded in accordance with local requirements. Official guidelines mandate that the product must not be disposed of in wastewater or household trash to avoid environmental release.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.